Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2021 Feb 28;21(1):72.
doi: 10.1186/s12890-021-01440-7.

Pulmonary vasodilation by sildenafil in acute intermediate-high risk pulmonary embolism: a randomized explorative trial

Asger Andersen  1 , Farhad Waziri  2 , Jacob Gammelgaard Schultz  2 , Sarah Holmboe  2 , Søren Warberg Becker  3 , Tage Jensen  4 , Hanne Maare Søndergaard  5 , Karen Kaae Dodt  6 , Ole May  7 , Ulrik Markus Mortensen  2 , Won Yong Kim  2 , Søren Mellemkjær  2 , Jens Erik Nielsen-Kudsk  2
Affiliations
Clinical Trial

Pulmonary vasodilation by sildenafil in acute intermediate-high risk pulmonary embolism: a randomized explorative trial

Asger Andersen et al. BMC Pulm Med. .

Abstract

Background: To investigate if acute pulmonary vasodilation by sildenafil improves right ventricular function in patients with acute intermediate-high risk pulmonary embolism (PE).

Methods: Single center, explorative trial. Patients with PE were randomized to a single oral dose of sildenafil 50 mg (n = 10) or placebo (n = 10) as add-on to conventional therapy. The time from hospital admission to study inclusion was 2.3 ± 0.7 days. Right ventricular function was evaluated immediately before and shortly after (0.5-1.5 h) randomization by right heart catheterization (RHC), trans-thoracic echocardiography (TTE), and cardiac magnetic resonance (CMR). The primary efficacy endpoint was cardiac index measured by CMR.

Results: Patients had acute intermediate-high risk PE verified by computed tomography pulmonary angiography, systolic blood pressure of 135 ± 18 (mean ± SD) mmHg, increased right ventricular/left ventricular ratio 1.1 ± 0.09 and increased troponin T 167 ± 144 ng/L. Sildenafil treatment did not improve cardiac index compared to baseline (0.02 ± 0.36 l/min/m2, p = 0.89) and neither did placebo (0.00 ± 0.34 l/min/m2, p = 0.97). Sildenafil lowered mean arterial blood pressure (- 19 ± 10 mmHg, p < 0.001) which was not observed in the placebo group (0 ± 9 mmHg, p = 0.97).

Conclusion: A single oral dose of sildenafil 50 mg did not improve cardiac index but lowered systemic blood pressure in patients with acute intermediate-high risk PE. The time from PE to intervention, a small patient sample size and low pulmonary vascular resistance are limitations of this study that should be considered when interpreting the results.

Trial registration: The trial was retrospectively registered at www.clinicaltrials.gov (NCT04283240) February 2nd 2020, https://clinicaltrials.gov/ct2/show/NCT04283240?term=NCT04283240&draw=2&rank=1 .

Keywords: PDE5 inhibition; Pulmonary embolism; Pulmonary vasodilation; Sildenafil.

PubMed Disclaimer

Conflict of interest statement

AA have received travel grants and lecturing fees from MSD, Medtronic, Abbot, Astra Zenica, Boehringer Ingelheim. JS has received lecturing fees from MSD. SB have received travel grants from Pfizer/BMS and Boehringer Ingelheim. HMS have received travel grants and lecturing fees from Astra Zeneca. SM, WYK, OM, SH, KKD, FW, JENK, TJ, UMM report no competing interests.

Figures

Fig. 1
Fig. 1
Study design. CMR cardiac magnetic resonance imaging. TTE trans-thoracic echocardiography. RCH right heart catheterization. R randomisation sildenafil 50 mg or placebo. *Measurement of blood pressure
Fig. 2
Fig. 2
a Primary efficacy endpoint. CI cardiac index measured by cardiac magnetic resonance imaging, b safety endpoint. MAP mean arterial blood pressure. ***p < 0.001
See this image and copyright information in PMC

References

    1. Kucher N, Rossi E, De Rosa M, Goldhaber SZ. Massive pulmonary embolism. Circulation. 2006;113(4):577–582. doi: 10.1161/CIRCULATIONAHA.105.592592. - DOI - PubMed
    1. Kasper W, Konstantinides S, Geibel A, Olschewski M, Heinrich F, Grosser KD, et al. Management strategies and determinants of outcome in acute major pulmonary embolism: results of a multicenter registry. J Am Coll Cardiol. 1997;30(5):1165–1171. doi: 10.1016/S0735-1097(97)00319-7. - DOI - PubMed
    1. Oger E. Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study. Group Groupe d'Etude de la Thrombose de Bretagne Occidentale. Thromb Haemost. 2000;83(5):657–660. doi: 10.1055/s-0037-1613887. - DOI - PubMed
    1. Nordström M, Lindblad B. Autopsy-verified venous thromboembolism within a defined urban population—the city of Malmö, Sweden. APMIS. 1998;106(3):378–384. doi: 10.1111/j.1699-0463.1998.tb01360.x. - DOI - PubMed
    1. Dalen JE, Alpert JS. Natural history of pulmonary embolism. Prog Cardiovasc Dis. 1975;17(4):259–270. doi: 10.1016/S0033-0620(75)80017-X. - DOI - PubMed

Publication types

Substances

Associated data